Logo Image
Feature|Videos|July 18, 2024

The Changing CDMO Landscape: Single-Use Technology, End-to-End Fill Finish Needs and Growth of Cell and Gene

Author(s)AGC Biologics

Key Takeaways

  • AGC Biologics’ new fill and finish offering for protein biologics
  • Facility expansions and partnerships to address common trends, like the U.S. Biosecure Act
SHOW MORE

Christoph Winterhalter, Chief Business Officer of AGC Biologics, highlights trends in single-use technology, the CDMO’s new fill-finish capabilities, facility expansions, the potential impact of the U.S. Biosecure Act, and the growing cell and gene market.

Watch this video to learn more:

  • AGC Biologics’ new fill and finish offering for protein biologics
  • Facility expansions and partnerships to address common trends, like the U.S. Biosecure Act
  • The power of single-use technology for developers
  • The CDMOs growing cell and gene commercial track record

Related Content